A combined post hoc analysis of LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6 demonstrated that 2G EGFR‐TKI afatinib was active (mostly in first‐line setting) in NSCLC patients that harbored certain types of uncommon EGFR mutations, especially for G719X, L861Q, and S768I, with an ORR of 71.1%, an mPFS of 10.7 months, and an mOS of 19.4 months, respectively.19 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.